deferasirox has been researched along with Kahler Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatia, R; Donohue, C; Forman, SJ; Krishnan, A; Meng, Z; Pullarkat, V; Synold, TW; Tomassetti, S; Yamamoto, VN | 1 |
| Arihara, Y; Hayasaka, N; Iyama, S; Kamihara, Y; Kato, J; Kawano, Y; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Sato, T; Sato, Y; Takada, K; Usami, M | 1 |
2 other study(ies) available for deferasirox and Kahler Disease
| Article | Year |
|---|---|
Iron chelators induce autophagic cell death in multiple myeloma cells.
Topics: Autophagy; Benzoates; Cell Line, Tumor; Cell Proliferation; Deferasirox; Deferoxamine; Drug Evaluation, Preclinical; Humans; Iron Chelating Agents; Multiple Myeloma; Primary Cell Culture; Reactive Oxygen Species; Triazoles | 2014 |
The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoates; beta Catenin; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Deferasirox; Dose-Response Relationship, Drug; Focal Adhesion Kinase 2; Humans; Iron; Iron Chelating Agents; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Phosphorylation; Reactive Oxygen Species; Time Factors; Triazoles; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2016 |